Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? (Q33820233)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Francesca De Luca

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Luca Malorni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Angelo Di Leo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Marta Pestrin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Francesca Galardi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

25 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

684-707

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

12 March 2020

copyright license

start time

25 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Development of a method to isolate circulating tumor cells using mesenchymal-based capture

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Vimentin as a poor prognostic factor for triple-negative breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Plasticity of disseminating cancer cells in patients with epithelial malignancies

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Tumor metastasis: molecular insights and evolving paradigms

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Adjuvant trastuzumab in HER2-positive breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

A new device for rapid isolation by size and characterization of rare circulating tumor cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Hallmarks of Cancer: The Next Generation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

HER2-positive circulating tumor cells in breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Molecular biomarker analyses using circulating tumor cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

The PI3K pathway as drug target in human cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumor cell analysis: technical and statistical considerations for application to the clinic

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Isolation of rare circulating tumour cells in cancer patients by microchip technology

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Cancer metastasis: building a framework

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

HER-2 gene amplification can be acquired as breast cancer progresses

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Amplification and over-expression of the neu oncogene in human breast carcinomas

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Overexpression of the c-erbB-2 protein in human breast tumor cell lines

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer

4 July 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Electronic sorting and recovery of single live cells from microlitre sized samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Multifactorial approach to predicting resistance to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4074798

External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study

29 October 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6020684

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

21 January 2018

1 reference

12 December 2020

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

1 reference

12 December 2020

Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells

1 reference

12 December 2020

Residual risk of breast cancer recurrence 5 years after adjuvant therapy

1 reference

12 December 2020

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

12 December 2020

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

1 reference

12 December 2020

Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer

1 reference

12 December 2020

Detection of circulating tumor cells in blood using an optimized density gradient centrifugation

1 reference

12 December 2020

Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS6020684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

24670368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24670368%20AND%20SRC:MED&resulttype=core&format=json